Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

dodecyl maltoside 2toripalimab 1pembrolizumab 1durvalumab 1apaziquone 1Mitomycin 1Imiquimod 1Gemcitabine 1Docetaxel 1Cystoscopy 1Biopsy 1BCG Vaccine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma in Situ × Gemcitabine × Clear all
NCT07189793 2025-09-24

OHAI-NMIBC-01

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
106 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡